サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1439620

吸入器 - 世界市場の考察、競合情勢、市場予測（2030年）

Respiratory Inhalers - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.94円
吸入器 - 世界市場の考察、競合情勢、市場予測（2030年）
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の吸入器の市場規模は、2022年に302億6,749万米ドル、2030年までに405億4,087万米ドルに達し、予測期間中（2022年～2028年）にCAGRで4.65%の成長が見込まれます。市場は、喘息、慢性閉塞性肺疾患（COPD）、嚢胞性線維症、喘息COPDオーバーラップ症候群などの呼吸器疾患の有病率の上昇、主要製薬企業によるデジタル技術の採用の急増、大気汚染の増加、喫煙者人口の増加、近年の製品の発売や規制当局の承認などの技術の進歩により、活況を呈する見込みであり、これらが予測期間（2024年～2030年）に吸入器市場全体を促進すると予測されます。

吸入器の市場力学

吸入器市場の注目すべき促進要因の1つは、喘息、COPD、嚢胞性線維症などの呼吸器疾患の有病率の上昇です。

例えば、世界保健機関（WHO）（2023）のデータによると、喘息は2019年に約2億6,200万人が罹患し、同年に世界で4億5,500万人の死亡を引き起こしました。また、Global Burden of Disease Study（2019）のデータによると、COPDの有病者数は世界で2億1,230万人と報告されており、2019年の1年間で330万人が死亡しています。喘息とCOPDに加えて、嚢胞性線維症の数値も常に上昇傾向にあります。March of Dimes Organization（2019）のデータによると、2019年に世界で約7万人～10万人が嚢胞性線維症に罹患しており、男性も女性も同じ割合で罹患しています。

さらに、大気汚染の増大も、今後数年間における吸入器の需要を促進すると予測されています。例えば、経済協力開発機構（2022）によると、2050年までに世界の温室効果ガス（GHG）排出は約50％増加すると予測されており、これは主にエネルギー関連のCO2排出が70％増加するためです。また、GHGの大気中濃度は2050年までにCO2換算で685ppmに達する可能性があり、その結果、今世紀末には世界の平均気温が産業革命前のレベルを3～6度上回ることになるとしています。

上記の要因とともに、技術開発は絶えず増加しており、吸入器市場の成長を後押ししています。例えば、2019年9月、Boehringer Ingelheimは最大6つのカートリッジで使用できる初の再使用可能なソフトミスト吸入器、Respimat® re-usableを発売し、カーボンフットプリントをさらに71％削減しました。

したがって、上記のすべての要因の相互作用が吸入器市場にプラスの影響を加え、予測期間に吸入器の需要をさらに押し上げると見込まれます。

しかし、代替の投与経路の利用可能性や、吸入器の高さ、これらのデバイスに伴う安全上の懸念が、吸入器市場の成長抑制要因として作用する可能性があります。

COVID-19パンデミックは、製造、供給、輸出入、吸入器市場のその他の関連活動の混乱につながるロックダウン指令、国境閉鎖などにより、当初の数ヶ月間に吸入器の市場成長が若干マイナスの影響を受けました。また、COVID-19の原因物質であるSARS-CoV-2ウイルスの蔓延の恐れと、パンデミックにまつわる不確実性のために、世界中の多くの国が、緊急の場合を除き肺機能検査（PFT）室の閉鎖を余儀なくされました。しかし、中等度から重度の喘息やコントロールされていない喘息に苦しむ人々は、COVID-19によって入院する可能性がより高かったです。COVID-19パンデミックはまた、世界中の人々の肺の健康に関する意識と懸念によりその後半には吸入器の増加につながり、肺機能の検査に向けた吸入器の活用をさらに加速させ、吸入器の市場成長を促進しました。

したがって、上記の要因、高いワクチン接種率、政府によるロックダウンの緩和とともに、吸入器の需要は増加し、吸入器市場全体を促進しています。

当レポートでは、世界の吸入器市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 吸入器市場レポートのイントロダクション

第2章 吸入器のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価
  • 財務ベンチマーク

第3章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 吸入器市場の主な要因の分析

  • 吸入器市場の促進要因
    • 肺疾患の有病率の上昇
    • 主要製薬企業によるデジタル技術の採用の急増
    • 世界中での大気汚染レベルの上昇
    • 喘息とCOPDの管理における患者の意識の向上
  • 吸入器市場の抑制要因と課題
    • 代替の投与経路の利用可能性
    • 吸入器のコストの増加
    • 機器に伴う安全上の懸念
  • 吸入器市場の機会
    • 吸入器の分野における新技術の研究開発
    • 主要企業の戦略的商業活動の拡大

第5章 吸入器市場のポーターのファイブフォース分析

第6章 吸入器市場に対するCOVID-19の影響分析

第7章 吸入器市場のレイアウト

  • 製品タイプ別
    • ドライパウダー吸入器
    • 定量噴霧式吸入器
    • ソフトミスト吸入器
    • ネブライザー
  • タイプ別
    • 従来式吸入器
    • スマート吸入器
  • 患者タイプ別
    • 成人
    • 小児
  • 適応症別
    • 喘息
    • COPD
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 吸入器市場：世界の企業シェア分析 - 主要3～5社

第9章 吸入器市場の企業と製品のプロファイル

  • Novartis AG
  • AstraZeneca
  • GSK plc.
  • B. CHIESI Farmaceutici S.p.A
  • Lupin
  • Zydus Lifesciences Limited
  • Teva Pharmaceutical Industries Ltd
  • OMRON Corporation
  • Koninklijke Philips N.V.
  • PARI GmbH
  • Boehringer Ingelheim International GmbH
  • Glenmark Pharmaceuticals Limited
  • H&T Presspart Manufacturing Ltd
  • Rossmax International Ltd
  • Promed Technology Co. Limited
  • HELTMAN Medikal A.S.
  • Pneuma Respiratory
  • Cipla Inc
  • Microlife Corporation
  • HONSUN

第10章 KOLの見解

第11章 プロジェクトのアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis on Respiratory Inhalers Market
  • Table 3: Respiratory Inhalers Market in Global (2021-2030)
  • Table 4: Respiratory Inhalers Market in Global by Product Type (2021-2030)
  • Table 5: Respiratory Inhalers Market in Global by Type (2021-2030)
  • Table 6: Respiratory Inhalers Market in Global by Patient Type (2021-2030)
  • Table 7: Respiratory Inhalers Market in Global by Indication (2021-2030)
  • Table 8: Respiratory Inhalers Market in Global by Geography (2021-2030)
  • Table 9: Respiratory Inhalers Market in North America (2021-2030)
  • Table 10: Respiratory Inhalers Market in North America by Country (2021-2030)
  • Table 11: Respiratory Inhalers Market in the US (2021-2030)
  • Table 12: Respiratory Inhalers Market in Canada (2021-2030)
  • Table 13: Respiratory Inhalers Market in Mexico (2021-2030)
  • Table 14: Respiratory Inhalers Market in Europe (2021-2030)
  • Table 15: Respiratory Inhalers Market in Europe by Country (2021-2030)
  • Table 16: Respiratory Inhalers Market in France (2021-2030)
  • Table 17: Respiratory Inhalers Market in Germany (2021-2030)
  • Table 18: Respiratory Inhalers Market in the United Kingdom (2021-2030)
  • Table 19: Respiratory Inhalers Market in Italy (2021-2030)
  • Table 20: Respiratory Inhalers Market in Spain (2021-2030)
  • Table 21: Respiratory Inhalers Market in Russia (2021-2030)
  • Table 22: Respiratory Inhalers Market in Rest of Europe (2021-2030)
  • Table 23: Respiratory Inhalers Market in APAC (2021-2030)
  • Table 24: Respiratory Inhalers Market in APAC by Country (2021-2030)
  • Table 25: Respiratory Inhalers Market in China (2021-2030)
  • Table 26: Respiratory Inhalers Market in Japan (2021-2030)
  • Table 27: Respiratory Inhalers Market in India (2021-2030)
  • Table 28: Respiratory Inhalers Market in Australia (2021-2030)
  • Table 29: Respiratory Inhalers Market in South Korea (2021-2030)
  • Table 30: Respiratory Inhalers Market in Rest of APAC (2021-2030)
  • Table 31: Respiratory Inhalers Market in Rest of World (2021-2030)
  • Table 32: Respiratory Inhalers Market in RoW by Region (2021-2030)
  • Table 33: Respiratory Inhalers Market in Middle East (2021-2030)
  • Table 34: Respiratory Inhalers Market in Africa (2021-2030)
  • Table 35: Respiratory Inhalers Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis on Respiratory Inhalers Market
  • Figure 3: Respiratory Inhalers Market in Global (2021-2030)
  • Figure 4: Respiratory Inhalers Market in Global by Product Type (2021-2030)
  • Figure 5: Respiratory Inhalers Market in Global by Type (2021-2030)
  • Figure 6: Respiratory Inhalers Market in Global by Patient Type (2021-2030)
  • Figure 7: Respiratory Inhalers Market in Global by Indication (2021-2030)
  • Figure 8: Respiratory Inhalers Market in Global by Geography (2021-2030)
  • Figure 9: Respiratory Inhalers Market in North America (2021-2030)
  • Figure 10: Respiratory Inhalers Market in North America by Country (2021-2030)
  • Figure 11: Respiratory Inhalers Market in the US (2021-2030)
  • Figure 12: Respiratory Inhalers Market in Canada (2021-2030)
  • Figure 13: Respiratory Inhalers Market in Mexico (2021-2030)
  • Figure 14: Respiratory Inhalers Market in Europe (2021-2030)
  • Figure 15: Respiratory Inhalers Market in Europe by Country (2021-2030)
  • Figure 16: Respiratory Inhalers Market in France (2021-2030)
  • Figure 17: Respiratory Inhalers Market in Germany (2021-2030)
  • Figure 18: Respiratory Inhalers Market in the United Kingdom (2021-2030)
  • Figure 19: Respiratory Inhalers Market in Italy (2021-2030)
  • Figure 20: Respiratory Inhalers Market in Spain (2021-2030)
  • Figure 21: Respiratory Inhalers Market in Russia (2021-2030)
  • Figure 22: Respiratory Inhalers Market in Rest of Europe (2021-2030)
  • Figure 23: Respiratory Inhalers Market in APAC (2021-2030)
  • Figure 24: Respiratory Inhalers Market in APAC by Country (2021-2030)
  • Figure 25: Respiratory Inhalers Market in China (2021-2030)
  • Figure 26: Respiratory Inhalers Market in Japan (2021-2030)
  • Figure 27: Respiratory Inhalers Market in India (2021-2030)
  • Figure 28: Respiratory Inhalers Market in Australia (2021-2030)
  • Figure 29: Respiratory Inhalers Market in South Korea (2021-2030)
  • Figure 30: Respiratory Inhalers Market in Rest of APAC (2021-2030)
  • Figure 31: Respiratory Inhalers Market in Rest of World (2021-2030)
  • Figure 32: Respiratory Inhalers Market in RoW by Region (2021-2030)
  • Figure 33: Respiratory Inhalers Market in Middle East (2021-2030)
  • Figure 34: Respiratory Inhalers Market in Africa (2021-2030)
  • Figure 35: Respiratory Inhalers Market in South America (2021-2030)
  • Figure 36: Market Drivers
  • Figure 37: Market Barriers
  • Figure 38: Marker Opportunities
  • Figure 39: PORTER'S Five Force Analysis
目次
Product Code: DIMDCL0454

Respiratory Inhalers Market By Product Type (Dry Powder Inhalers, Metered Dosed Inhalers, Soft Mist Inhalers, Nebulizers[Mesh Nebulizers, Jet Nebulizers, Ultrasonic Nebulizers]), By Type (Conventional Inhaler Devices And Smart Inhaler Devices), By Patient Type (Adult And Pediatric), By Indication (Asthma, COPD, Others) and by geography is estimated to register growth at a remarkable CAGR during the forecast period 2024-2030 owing to the increasing prevalence of respiratory disorders such as asthma, COPD, and others, the rising air pollution and the growing number of product development activities such as product launches and regulatory approvals

The global respiratory inhalers market was valued at USD 30,267.49 million in 2022 and is estimated to grow at a CAGR of 4.65% during the forecast period of (2022-2028) to reach USD 40,540.87 million by 2030. The Respiratory Inhalers market is slated to witness prosperity owing to the rising prevalence of respiratory disorders such as asthma, Chronic Obstructive Pulmonary Disorder (COPD), cystic fibrosis, asthma-COPD overlap syndrome, and others, the surge in the adoption of digital technology by key pharmaceutical players, the rising air pollution, increase in the population of smokers, and the growing technological advancements such as recent product launches and regulatory approvals is expected to drive the overall market for Respiratory Inhalers during the forecast period (2024-2030).

Respiratory Inhalers Market Dynamics:

One of the noteworthy drivers of the respiratory inhalers market is the rising prevalence of respiratory disorders such as asthma, COPD, cystic fibrosis, among others.

For example, as per data by the World Health Organization (2023), asthma affected approximately 262 million people in 2019, causing 455,000 deaths in the same year, globally. Also, according to data by the Global Burden of Disease Study (2019), there were 212.3 million prevalent cases of COPD reported globally, accounting for 3.3 million deaths in the year 2019. In addition to asthma and COPD, the numbers for cystic fibrosis are constantly on the rise. As per data by the March of Dimes Organization (2019), about 70,000 to 100,000 people had cystic fibrosis in the year 2019 globally, affecting males and females at the same rate.

Moreover, the rising air pollution is also expected to drive the demand for respiratory inhalers in the upcoming years. For instance, as per the Organization for Economic Co-operation and Development 2022, by 2050 the emission of global greenhouse gases (GHGs) could be anticipated to increase by about 50%, majorly owing to 70% growth in energy-related CO2 emissions. It also stated that the atmospheric concentration of GHGs could reach 685 parts per million (ppm) CO2- equivalents by 2050, resulting in the global average temperatures to be 3 to 6 degree Celsius above the pre-industrial levels by the end of the century.

Along with the factors mentioned above, the number of technological developments are constantly increasing, bolstering the growth of the respiratory inhalers market. For example, in September 2019, Boehringer Ingelheim launched the first reusable soft mist inhaler Respimat® re-usable that can be used with up to six cartridges, reducing the carbon footprint further by 71%.

Thus, the interplay of all the above-mentioned factors is expected to add a positive impact on the respiratory inhalers market, which will further boost the demand for respiratory inhalers during the forecast period.

However, the availability of alternate route of administration, high of inhalers and the safety concerns coupled with these devices, may act as restraining factors for the respiratory inhalers market growth.

The COVID- 19 pandemic had a slightly negative impact on the market growth of respiratory inhalers during the initial few months owing to the lockdown impositions, border closures, and others leading to disruption in the manufacturing, supply, import, export, and other related activities of the respiratory inhalers market. Also, owing to the fear of spread of SARS-CoV-2 virus which is the causative agent for COVID-19 and uncertainties revolving around the pandemic, many countries across the world were forced to close down pulmonary function tests (PFT) laboratories except in case of emergencies. However, people suffering from moderate-to-severe or uncontrolled asthma were more likely to get hospitalized from COVID-19. The COVID -19 pandemic also led to rise in respiratory inhalers in the later half owing to the awareness and concerns regarding lung health among the people across the world which is further accelerated the utilization of respiratory inhalers for the testing of lung function, driving the market growth for respiratory inhalers.

Thus, along with the above-mentioned factors, high vaccination rates and relaxations in the government-imposed lockdown, the demand for respiratory inhalers is subjected to increase driving the overall market for respiratory inhalers.

Respiratory Inhalers Market Segment Analysis:

Respiratory Inhalers market by product type (dry powder inhalers, metered dosed inhalers, soft mist inhalers, nebulizers [mesh nebulizers, jet nebulizers, ultrasonic nebulizers]), type (conventional inhaler devices and smart inhaler devices), patient type (adult and pediatric), indication (asthma, COPD, others), and geography (North America, Europe, Asia-Pacific, and Rest of the World).

Based on the type segment, the smart inhaler devices is expected to hold the maximum revenue share in the respiratory inhalers market and was valued at USD 46.50 million in 2022 and will grow at a CAGR of 15.63% during the forecast period (2022-2028) to reach USD 113.20 million by 2030.

This can be attributed to the technological superiority, compatibility, and the increasing product development activities such as product regulatory approvals in the smart inhaler devices segment during the forecast period.

Smart inhalers serve enormous benefits for adults and the geriatric population who may find difficulties in taking up the same amount of puffs due to unequal breath. According to the U.S Department of Health and Human Services (2023), with old age, the muscles supporting breathing and the diaphragm, becomes weakened, preventing from breathing enough air in or out. Smart inhalers can be employed in these cases. Smart inhalers, equipped with sensors attach to conventional inhalers and helps to keep a track of timing of medication. Also, being Bluetooth-enabled, they can be remotely coupled with a computer or a smart device like a phone or tablet to transport data from the smart inhaler automatically.

Along with numerous advantages of the device, the growing product approvals is also expected to bolster the demand for smart inhalers in the forthcoming years. For instance, in January, 2020, FDA approved the CapMedic smart inhaler cap from Cognita Labs, which is capable of transmitting signals to patients to use inhalers correctly.

Hence, the interplay of all the aforementioned factors is anticipated to propel the market for aspheric monofocal Respiratory Inhalers during the forecast period.

North America is expected to dominate the overall Respiratory Inhalers Market:

Among all the regions, North America is expected to lead in revenue generation in the global respiratory inhalers market and was valued at USD 13,514.14 million in 2022. It will grow at a CAGR of 4.08% during the forecast period from 2024 to 2030 to reach USD 17,525.98 million by 2030.

This domination is due to the increasing prevalence of various respiratory disorders such as chronic obstructive pulmonary disorder (COPD), asthma, among others, increasing exposure of smoking, dust, and chemicals, and various initiatives by government bodies for respiratory healthcare, and others in the North America region. Furthermore, research and development activities in the region associated with the launch of new respiratory inhalers are also driving the market growth in North America.

As per the data published by World Health Organization (WHO) 2022, approximately 25 million people in the United States had asthma in the year 2020 including 4.2 million children, which equals about 1 in every 13 people. According to the National Center for Health Statistics 2019-2020, stated that the percentage of COPD, emphysema, or chronic bronchitis for adults aged 18 and over, in the United States, increased from 4.6% in 2019 to 5.0% in 2020.

In other countries of North America such as Canada, the numbers for respiratory ailments are substantially increasing. According to statistics by the Lung Association 2020-2022, it was concluded that about 2.6 million Canadians were living with asthma in the year 2020 - 2022.

In addition to the above factors, the growing product development activities is also expected to drive the demand for respiratory inhalers in the North America region. For instance, in September 2020, Teva Respiratory, LLC., a United States affiliate of Teva Pharmaceutical Industries Ltd., announced the launch of AirDuo® Digihaler® inhalation powder and ArmonAir® Digihaler® inhalation powder, two digital maintenance inhalers for patients with asthma. In a similar instance, in October 2020, Teva Canada, a subsidiary of Teva Pharmaceutical Industries Ltd., declared the product availability of Aermony RespiClick in Canada. The inhaler is indicated for the maintenance treatment of steroid-responsive bronchial asthma as prophylactic therapy in patients 12 years of age and older and offered in a simple-to-use inhaler.

Therefore, the increasing product developmental activities, the rising prevalence of respiratory disorders and the large patient population associated with them, is expected to drive the demand for respiratory inhalers, thereby driving the overall respiratory inhalers during the forecast period.

Respiratory Inhalers Market Key Players:

Some of the key market players operating in the respiratory inhalers market include Novartis AG, AstraZeneca, GSK plc., CHIESI Farmaceutici S.p.A, Lupin, Zydus Lifesciences Limited, Teva Pharmaceutical Industries Ltd, OMRON Corporation, Koninklijke Philips N.V., PARI GmbH, . Boehringer Ingelheim International GmbH, Glenmark Pharmaceuticals Limited, H&T Presspart Manufacturing Ltd., Rossmax International Ltd, Promed Technology Co. Limited, HELTMAN Medikal A.S., Pneuma Respiratory, Cipla Inc, Microlife Corporation, HONSUN, and others.

Recent Developmental Activities in Respiratory Inhalers Market:

In October 2020, Teva Canada, a subsidiary of Teva Pharmaceutical Industries Ltd., declared the product availability of Aermony RespiClick in Canada. The inhaler is indicated for the maintenance treatment of steroid-responsive bronchial asthma as prophylactic therapy in patients 12 years of age and older and offered in a simple-to-use inhaler.

In September 2020, Teva Respiratory, LLC., a United States affiliate of Teva Pharmaceutical Industries Ltd., announced the launch of AirDuo® Digihaler® inhalation powder and ArmonAir® Digihaler® inhalation powder, two digital maintenance inhalers for patients with asthma.

In September 2019, Boehringer Ingelheim launched the first reusable soft mist inhaler Respimat® re-usable that can be used with up to six cartridges, reducing the carbon footprint further by 71%.

Key Takeaways from the Respiratory Inhalers Market Report Study

  • Market size analysis for current respiratory inhalers market size (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the respiratory inhalers market.
  • Top key product/services/technology developments, mergers, acquisitions, partnerships, joint ventures happened for last 3 years
  • Key companies dominating the global respiratory inhalers market.
  • Various opportunities available for the other competitor in the respiratory inhalers market space.
  • What are the top performing segments in 2023? How these segments will perform in 2030.
  • Which are the top-performing regions and countries in the current respiratory inhalers market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for respiratory inhalers market growth in the coming future?

Target Audience who can be benefited from this Respiratory Inhalers Market Report Study

  • Respiratory Inhalers products providers
  • Research organizations and consulting companies
  • Respiratory Inhalers-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in respiratory inhalers
  • Various end users who want to know more about the respiratory inhalers market and latest technological developments in the respiratory inhalers market.

Frequently Asked Questions for Respiratory Inhalers Market:

1. What are the Respiratory Inhalers?

Respiratory inhalers are portable medical devices used to treat disorders of the respiratory tract such as asthma and chronic obstructive pulmonary disease (COPD). Exacerbations of these persistent disorders are prevented and treated using respiratory inhalers.

2. What is the market for the global Respiratory Inhalers?

The global Respiratory Inhalers market was valued at USD 30,267.49 million in 2022 and is estimated to grow at a CAGR of 4.65% during the forecast period (2022-2028) to reach USD 40,540.87 million by 2030.

3. What are the drivers for the global Respiratory Inhalers market?

The Respiratory Inhalers market is slated to witness prosperity owing to the rising prevalence of respiratory disorders such as asthma, Chronic Obstructive Pulmonary Disorder (COPD), cystic fibrosis, asthma-COPD overlap syndrome, and others, the surge in the adoption of digital technology by key pharmaceutical players, the rising air pollution, increase in the population of smokers, and the growing technological advancements such as recent product launches and regulatory approvals is expected to drive the overall market for Respiratory Inhalers during the forecast period (2024-2030).

4. Who are the key players operating in the global Respiratory Inhalers market?

Some of the key market players operating in the respiratory inhalers market include Novartis AG, AstraZeneca, GSK plc., CHIESI Farmaceutici S.p.A, Lupin, Zydus Lifesciences Limited, Teva Pharmaceutical Industries Ltd, OMRON Corporation, Koninklijke Philips N.V., PARI GmbH, . Boehringer Ingelheim International GmbH, Glenmark Pharmaceuticals Limited, H&T Presspart Manufacturing Ltd., Rossmax International Ltd, Promed Technology Co. Limited, HELTMAN Medikal A.S., Pneuma Respiratory, Cipla Inc, Microlife Corporation, HONSUN, and others.

5. Which region has the highest share in the Respiratory Inhalers market?

North America is expected to dominate the overall Respiratory Inhalers market during the forecast period, 2024 to 2030. This can be ascribed to the increasing prevalence of various respiratory disorders such as chronic obstructive pulmonary disorder (COPD), asthma, among others, increasing exposure of smoking, dust, and chemicals, and various initiatives by government bodies for respiratory healthcare, and others in the North America region. Furthermore, research and development activities in the region associated with the launch of new respiratory inhalers are also driving the market growth in North America.

Table of Contents

1.Respiratory Inhalers market Report Introduction

2.Respiratory Inhalers Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment
  • 2.4. Financial Benchmarking

3. Regulatory Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Respiratory Inhalers market Key Factors Analysis

  • 4.1. Respiratory Inhalers market Drivers
    • 4.1.1. Rising prevalence of pulmonary disorders
    • 4.1.2. Surge in adoption of digital technology by key pharmaceutical players
    • 4.1.3. Augmented levels of air pollution globally
    • 4.1.4. Increasing awareness amongst patients in management of asthma and COPD
  • 4.2. Respiratory Inhalers market Restraints and Challenges
    • 4.2.1. Availability of alternate route of administration
    • 4.2.2. Increasing cost of inhalers
    • 4.2.3. Safety concerns coupled with the devices
  • 4.3. Respiratory Inhalers market Opportunities
    • 4.3.1. Research and development of novel technologies in the field of respiratory inhalers
    • 4.3.2. Expansion of strategic commercial activities amongst the key players

5. Respiratory Inhalers market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Respiratory Inhalers market

7. Respiratory Inhalers market Layout

  • 7.1. By Product Type
    • 7.1.1. Dry Powder Inhalers
    • 7.1.2. Metered Dosed Inhalers
    • 7.1.3. Soft Mist Inhalers
    • 7.1.4. Nebulizers
      • 7.1.4.1. Jet Nebulizers
      • 7.1.4.2. Ultrasonic Nebulizers
      • 7.1.4.3. Mesh Nebulizers
  • 7.2. By Type
    • 7.2.1. Conventional Inhaler Devices
    • 7.2.2. Smart Inhaler Devices
  • 7.3. By Patient Type
    • 7.3.1. Adult
    • 7.3.2. Pediatric
  • 7.4. By Indication
    • 7.4.1. Asthma
    • 7.4.2. COPD
    • 7.4.3. Others
  • 7.5. By Geography
    • 7.5.1. North America
      • 7.5.1.1. United States Respiratory Inhalers Market in USD million (2021-2030)
      • 7.5.1.2. Canada Respiratory Inhalers Market in USD million (2021-2030)
      • 7.5.1.3. Mexico Respiratory Inhalers Market in USD million (2021-2030)
    • 7.5.2. Europe
      • 7.5.2.1. France Respiratory Inhalers Market in USD million (2021-2030)
      • 7.5.2.2. Germany Respiratory Inhalers Market in USD million (2021-2030)
      • 7.5.2.3. United Kingdom Respiratory Inhalers Market in USD million (2021-2030)
      • 7.5.2.4. Italy Respiratory Inhalers Market in USD million (2021-2030)
      • 7.5.2.5. Spain Respiratory Inhalers Market in USD million (2021-2030)
      • 7.5.2.6. Russia Respiratory Inhalers Market in USD million (2021-2030)
      • 7.5.2.7. Rest of Europe Respiratory Inhalers Market in USD million (2021-2030)
    • 7.5.3. Asia-Pacific
      • 7.5.3.1. China Respiratory Inhalers Market in USD million (2021-2030)
      • 7.5.3.2. Japan Respiratory Inhalers Market in USD million (2021-2030)
      • 7.5.3.3. India Respiratory Inhalers Market in USD million (2021-2030)
      • 7.5.3.4. Australia Respiratory Inhalers Market in USD million (2021-2030)
      • 7.5.3.5. South Korea Respiratory Inhalers Market in USD million (2021-2030)
      • 7.5.3.6. Rest of Asia Pacific Respiratory Inhalers Market in USD million (2021-2030)
    • 7.5.4. Rest of the World (RoW)
      • 7.5.4.1. Middle East Respiratory Inhalers Market in USD million (2021-2030)
      • 7.5.4.2. Africa Respiratory Inhalers Market in USD million (2021-2030)
      • 7.5.4.3. South America Respiratory Inhalers Market in USD million (2021-2030)

8. Respiratory Inhalers Market Global Company Share Analysis - Key 3-5 Companies

9. Respiratory Inhalers Market Company and Product Profiles

  • 9.1. Novartis AG
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4. Product Listing
    • 9.1.5. Entropy
  • 9.2. AstraZeneca
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4. Product Listing
    • 9.2.5. Entropy
  • 9.3. GSK plc.
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4. Product Listing
    • 9.3.5. Entropy
  • 9.4. B. CHIESI Farmaceutici S.p.A
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4. Product Listing
    • 9.4.5. Entropy
  • 9.5. Lupin
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4. Product Listing
    • 9.5.5. Entropy
  • 9.6. Zydus Lifesciences Limited
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4. Product Listing
    • 9.6.5. Entropy
  • 9.7. Teva Pharmaceutical Industries Ltd
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4. Product Listing
    • 9.7.5. Entropy
  • 9.8. OMRON Corporation
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4. Product Listing
    • 9.8.5. Entropy
  • 9.9. Koninklijke Philips N.V.
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4. Product Listing
    • 9.9.5. Entropy
  • 9.10. PARI GmbH
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4. Product Listing
    • 9.10.5. Entropy
  • 9.11. Boehringer Ingelheim International GmbH
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4. Product Listing
    • 9.11.5. Entropy
  • 9.12. Glenmark Pharmaceuticals Limited
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4. Product Listing
    • 9.12.5. Entropy
  • 9.13. H&T Presspart Manufacturing Ltd
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4. Product Listing
    • 9.13.5. Entropy
  • 9.14. Rossmax International Ltd
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4. Product Listing
    • 9.14.5. Entropy
  • 9.15. Promed Technology Co. Limited
    • 9.15.1. Company Overview
    • 9.15.2. Company Snapshot
    • 9.15.3. Financial Overview
    • 9.15.4. Product Listing
    • 9.15.5. Entropy
  • 9.16. HELTMAN Medikal A.S.
    • 9.16.1. Company Overview
    • 9.16.2. Company Snapshot
    • 9.16.3. Financial Overview
    • 9.16.4. Product Listing
    • 9.16.5. Entropy
  • 9.17. Pneuma Respiratory
    • 9.17.1. Company Overview
    • 9.17.2. Company Snapshot
    • 9.17.3. Financial Overview
    • 9.17.4. Product Listing
    • 9.17.5. Entropy
  • 9.18. Cipla Inc
    • 9.18.1. Company Overview
    • 9.18.2. Company Snapshot
    • 9.18.3. Financial Overview
    • 9.18.4. Product Listing
    • 9.18.5. Entropy
  • 9.19. Microlife Corporation
    • 9.19.1. Company Overview
    • 9.19.2. Company Snapshot
    • 9.19.3. Financial Overview
    • 9.19.4. Product Listing
    • 9.19.5. Entropy
  • 9.20. HONSUN
    • 9.20.1. Company Overview
    • 9.20.2. Company Snapshot
    • 9.20.3. Financial Overview
    • 9.20.4. Product Listing
    • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us